Portal vein obstruction arises as a result of various metabolic and autoimmune disorders. This condition is typically caused by the formation of blood clots within the portal vasculature. However, it can also occur due to the growth of malignant tumors in the area. Portal vein thrombosis is the most common cause of portal vein obstruction.
It occurs when blood clots form within the portal vein, which is responsible for carrying blood from the gastrointestinal tract to the liver. This can result in a blockage of blood flow to the liver, leading to various complications such as liver dysfunction, portal hypertension, and ascites.
Malignant tumors can also cause portal vein obstruction. These tumors can grow within or near the portal vein, obstructing blood flow and causing similar complications to those associated with thrombosis.
Epidemiology
The prevalence varies across different populations, with estimates ranging from 1.6% to 16%. However, the incidence tends to be higher in patients with cirrhosis caused by alcohol use disorder or Hepatitis B infection. The prevalence of portal vein occlusion is relatively low, around 1%, in patients with compensated liver cirrhosis.
In contrast, it can be as high as 25% in patients awaiting liver transplantation. Several factors contribute to this higher incidence in transplant patients. For instance, these patients often have advanced underlying liver disease, which may increase the risk of developing portal vein occlusion. Additionally, immobility due to more severe ascites may also contribute to the development of this condition.
Another possible factor is a higher degree of imbalance of clotting factors in liver transplant patients, which can increase the risk of thrombosis. Other factors that may increase the risk of portal vein occlusion in transplant patients include immunosuppressive medications and post-transplant complications, such as graft rejection or infection.
Anatomy
Pathophysiology
The portal vein carries nutrient-rich blood from the digestive system to the liver. Any obstruction in this vein can lead to a variety of complications. One of the common causes of portal vein obstruction is thrombosis. The causes of portal vein thrombosis can vary depending on the patient’s underlying condition. For instance, in patients with liver cirrhosis, the imbalance of coagulation factors and endothelial dysfunction can lead to a hypercoagulable state, increasing the risk of thrombosis.
The presence of high levels of thrombin in the blood of cirrhotic patients can further contribute to the development of clots. In addition, stasis or reduced portal velocity can also increase the risk of thrombosis. Some studies suggest that beta blockers may also be associated with an increased risk of portal vein thrombosis, although further research is needed to confirm this link.
In cancer patients, the obstruction of the portal vein can occur for various reasons, including direct invasion by a growing tumor or hypercoagulability caused by cancer. Regardless of the underlying cause, the obstruction of the portal vein can lead to the development of collateral veins within ten weeks, which can cause a range of complications.
Ascites is a common complication of portal vein thrombosis. In addition, if the thrombus extends into the mesenteric vein, it can lead to bowel ischemia, which is a serious condition that can cause abdominal pain, nausea, and vomiting. It is worth noting that portal vein obstruction usually does not affect liver function unless the organ is already diseased. However, the development of collateral veins can cause portal hypertension, which is a condition that increases pressure in the portal vein and can cause damage to the liver, spleen, and other organs.
Etiology
There are inherited and acquired causes of portal vein obstruction. The inherited causes are protein C, protein S deficiency, prothrombin gene mutation, and factor V Leiden mutation.
Acquired causes are sepsis, malignancy, peripartum, burns, liver disease, oral contraceptives, and inflammatory diseases. In adults, most cases occur due to cirrhosis followed by neoplasms. In children, intra-abdominal infection causes most cases of portal vein obstruction.
Genetics
Prognostic Factors
The prognosis for this condition is generally good, with a 10-year mortality rate of 25% and an overall mortality rate of around 10%. However, if the patient has cirrhosis or cancer, the prognosis is worse and depends on the underlying condition.
Esophageal varices, which can be a complication of this condition, have a high mortality rate. Children usually have a better prognosis since the cause is rarely related to cancer or advanced liver disease.
Clinical History
Clinical History
Ascites is a common complication in patients with portal vein obstruction. In cases where malignancies are the primary cause of splenomegaly, signs of the neoplasm may also be evident. For example, patients with pancreatic carcinoma may present with fatigue and jaundice, while patients with hepatocellular carcinoma or cholangiocarcinoma may have jaundice and associated pruritis.
Splenomegaly is a common manifestation in patients with portal vein obstruction, and its incidence varies. In some cases, such as liver cirrhosis, additional signs like spider angiomata and palmar erythema may also be present due to increased pressure in the portal vein. Collaterals may also form, leading to the development of caput-medusae, hemorrhoids, and enlarged esophageal veins, which can result in upper gastrointestinal bleeding.
Physical Examination
Physical Examination
Children with growth retardation may experience abnormalities in the extrahepatic biliary tree, which can occur due to compression from choledochal or periportal varices or ischemic stricturing. This can lead to a range of symptoms, including jaundice, hemobilia, cholangitis, cholecystitis, or a mass in the liver’s hilum region that can be mistaken for a cholangiocarcinoma.
Stigmata of chronic liver diseases, such as spider angiomata or palmar erythema, are often found with underlying liver disease. Mild hepatomegaly is also frequently present, as is tenderness in the right upper quadrant of the abdomen. It is important to note that these symptoms in a child may indicate an underlying liver disease or other medical condition.
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Differential Diagnoses
Arsenic toxicity
Budd-Chiari syndrome
Cirrhosis
Primary biliary cirrhosis
Schistosomiasis
Sarcoidosis
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
Treatment of thrombosis in patients with cirrhosis can be challenging as balancing the use of anticoagulants with the risk of bleeding can be difficult. Selecting the appropriate anticoagulant can also be problematic, as each option has its benefits and drawbacks. LMWH and vitamin K antagonists have been successfully used to treat thrombosis in cirrhotic patients, but monitoring warfarin treatment can be challenging due to the patient’s baseline elevated INR.
Acute portal vein thrombosis should be treated with LMWH for at least three months and switched to oral anticoagulant agents after patient stabilization. Surgical modalities such as shunt surgery and the Sugiura procedure are options for treating portal vein occlusion associated with variceal bleeding. However, their use should be limited to recovery therapy when anticoagulation has failed, and invasive procedures are not contraindicated.
Shunt surgery is not recommended for patients with cirrhosis as it has a high mortality rate. Experts suggest endoscopic treatment and propranolol for patients with recurrent bleeding. If shunt surgery is necessary, a distal splenorenal shunt is recommended, with the option for splenectomy if the splenic vein is thrombosed.
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
Future Trends
Media Gallary
References
https://www.ncbi.nlm.nih.gov/books/NBK541134/
News
Vaping’s ‘95% Safer’ Claim Debated for Youth Health
Posted on
News
Google DeepMind’s AI Revolutionizes the Search for Disease Genes
Posted on
News
Mosquitoes Pose New Challenge to Public Health
Posted on
News
3D-Printed e3-skin Redefines Wearable Health Monitoring
Portal vein obstruction arises as a result of various metabolic and autoimmune disorders. This condition is typically caused by the formation of blood clots within the portal vasculature. However, it can also occur due to the growth of malignant tumors in the area. Portal vein thrombosis is the most common cause of portal vein obstruction.
It occurs when blood clots form within the portal vein, which is responsible for carrying blood from the gastrointestinal tract to the liver. This can result in a blockage of blood flow to the liver, leading to various complications such as liver dysfunction, portal hypertension, and ascites.
Malignant tumors can also cause portal vein obstruction. These tumors can grow within or near the portal vein, obstructing blood flow and causing similar complications to those associated with thrombosis.
The prevalence varies across different populations, with estimates ranging from 1.6% to 16%. However, the incidence tends to be higher in patients with cirrhosis caused by alcohol use disorder or Hepatitis B infection. The prevalence of portal vein occlusion is relatively low, around 1%, in patients with compensated liver cirrhosis.
In contrast, it can be as high as 25% in patients awaiting liver transplantation. Several factors contribute to this higher incidence in transplant patients. For instance, these patients often have advanced underlying liver disease, which may increase the risk of developing portal vein occlusion. Additionally, immobility due to more severe ascites may also contribute to the development of this condition.
Another possible factor is a higher degree of imbalance of clotting factors in liver transplant patients, which can increase the risk of thrombosis. Other factors that may increase the risk of portal vein occlusion in transplant patients include immunosuppressive medications and post-transplant complications, such as graft rejection or infection.
The portal vein carries nutrient-rich blood from the digestive system to the liver. Any obstruction in this vein can lead to a variety of complications. One of the common causes of portal vein obstruction is thrombosis. The causes of portal vein thrombosis can vary depending on the patient’s underlying condition. For instance, in patients with liver cirrhosis, the imbalance of coagulation factors and endothelial dysfunction can lead to a hypercoagulable state, increasing the risk of thrombosis.
The presence of high levels of thrombin in the blood of cirrhotic patients can further contribute to the development of clots. In addition, stasis or reduced portal velocity can also increase the risk of thrombosis. Some studies suggest that beta blockers may also be associated with an increased risk of portal vein thrombosis, although further research is needed to confirm this link.
In cancer patients, the obstruction of the portal vein can occur for various reasons, including direct invasion by a growing tumor or hypercoagulability caused by cancer. Regardless of the underlying cause, the obstruction of the portal vein can lead to the development of collateral veins within ten weeks, which can cause a range of complications.
Ascites is a common complication of portal vein thrombosis. In addition, if the thrombus extends into the mesenteric vein, it can lead to bowel ischemia, which is a serious condition that can cause abdominal pain, nausea, and vomiting. It is worth noting that portal vein obstruction usually does not affect liver function unless the organ is already diseased. However, the development of collateral veins can cause portal hypertension, which is a condition that increases pressure in the portal vein and can cause damage to the liver, spleen, and other organs.
There are inherited and acquired causes of portal vein obstruction. The inherited causes are protein C, protein S deficiency, prothrombin gene mutation, and factor V Leiden mutation.
Acquired causes are sepsis, malignancy, peripartum, burns, liver disease, oral contraceptives, and inflammatory diseases. In adults, most cases occur due to cirrhosis followed by neoplasms. In children, intra-abdominal infection causes most cases of portal vein obstruction.
The prognosis for this condition is generally good, with a 10-year mortality rate of 25% and an overall mortality rate of around 10%. However, if the patient has cirrhosis or cancer, the prognosis is worse and depends on the underlying condition.
Esophageal varices, which can be a complication of this condition, have a high mortality rate. Children usually have a better prognosis since the cause is rarely related to cancer or advanced liver disease.
Clinical History
Ascites is a common complication in patients with portal vein obstruction. In cases where malignancies are the primary cause of splenomegaly, signs of the neoplasm may also be evident. For example, patients with pancreatic carcinoma may present with fatigue and jaundice, while patients with hepatocellular carcinoma or cholangiocarcinoma may have jaundice and associated pruritis.
Splenomegaly is a common manifestation in patients with portal vein obstruction, and its incidence varies. In some cases, such as liver cirrhosis, additional signs like spider angiomata and palmar erythema may also be present due to increased pressure in the portal vein. Collaterals may also form, leading to the development of caput-medusae, hemorrhoids, and enlarged esophageal veins, which can result in upper gastrointestinal bleeding.
Physical Examination
Children with growth retardation may experience abnormalities in the extrahepatic biliary tree, which can occur due to compression from choledochal or periportal varices or ischemic stricturing. This can lead to a range of symptoms, including jaundice, hemobilia, cholangitis, cholecystitis, or a mass in the liver’s hilum region that can be mistaken for a cholangiocarcinoma.
Stigmata of chronic liver diseases, such as spider angiomata or palmar erythema, are often found with underlying liver disease. Mild hepatomegaly is also frequently present, as is tenderness in the right upper quadrant of the abdomen. It is important to note that these symptoms in a child may indicate an underlying liver disease or other medical condition.
Differential Diagnoses
Arsenic toxicity
Budd-Chiari syndrome
Cirrhosis
Primary biliary cirrhosis
Schistosomiasis
Sarcoidosis
Treatment of thrombosis in patients with cirrhosis can be challenging as balancing the use of anticoagulants with the risk of bleeding can be difficult. Selecting the appropriate anticoagulant can also be problematic, as each option has its benefits and drawbacks. LMWH and vitamin K antagonists have been successfully used to treat thrombosis in cirrhotic patients, but monitoring warfarin treatment can be challenging due to the patient’s baseline elevated INR.
Acute portal vein thrombosis should be treated with LMWH for at least three months and switched to oral anticoagulant agents after patient stabilization. Surgical modalities such as shunt surgery and the Sugiura procedure are options for treating portal vein occlusion associated with variceal bleeding. However, their use should be limited to recovery therapy when anticoagulation has failed, and invasive procedures are not contraindicated.
Shunt surgery is not recommended for patients with cirrhosis as it has a high mortality rate. Experts suggest endoscopic treatment and propranolol for patients with recurrent bleeding. If shunt surgery is necessary, a distal splenorenal shunt is recommended, with the option for splenectomy if the splenic vein is thrombosed.
https://www.ncbi.nlm.nih.gov/books/NBK541134/
medtigo
Portal Vein Obstruction
Updated :
August 24, 2023
Portal vein obstruction arises as a result of various metabolic and autoimmune disorders. This condition is typically caused by the formation of blood clots within the portal vasculature. However, it can also occur due to the growth of malignant tumors in the area. Portal vein thrombosis is the most common cause of portal vein obstruction.
It occurs when blood clots form within the portal vein, which is responsible for carrying blood from the gastrointestinal tract to the liver. This can result in a blockage of blood flow to the liver, leading to various complications such as liver dysfunction, portal hypertension, and ascites.
Malignant tumors can also cause portal vein obstruction. These tumors can grow within or near the portal vein, obstructing blood flow and causing similar complications to those associated with thrombosis.
The prevalence varies across different populations, with estimates ranging from 1.6% to 16%. However, the incidence tends to be higher in patients with cirrhosis caused by alcohol use disorder or Hepatitis B infection. The prevalence of portal vein occlusion is relatively low, around 1%, in patients with compensated liver cirrhosis.
In contrast, it can be as high as 25% in patients awaiting liver transplantation. Several factors contribute to this higher incidence in transplant patients. For instance, these patients often have advanced underlying liver disease, which may increase the risk of developing portal vein occlusion. Additionally, immobility due to more severe ascites may also contribute to the development of this condition.
Another possible factor is a higher degree of imbalance of clotting factors in liver transplant patients, which can increase the risk of thrombosis. Other factors that may increase the risk of portal vein occlusion in transplant patients include immunosuppressive medications and post-transplant complications, such as graft rejection or infection.
The portal vein carries nutrient-rich blood from the digestive system to the liver. Any obstruction in this vein can lead to a variety of complications. One of the common causes of portal vein obstruction is thrombosis. The causes of portal vein thrombosis can vary depending on the patient’s underlying condition. For instance, in patients with liver cirrhosis, the imbalance of coagulation factors and endothelial dysfunction can lead to a hypercoagulable state, increasing the risk of thrombosis.
The presence of high levels of thrombin in the blood of cirrhotic patients can further contribute to the development of clots. In addition, stasis or reduced portal velocity can also increase the risk of thrombosis. Some studies suggest that beta blockers may also be associated with an increased risk of portal vein thrombosis, although further research is needed to confirm this link.
In cancer patients, the obstruction of the portal vein can occur for various reasons, including direct invasion by a growing tumor or hypercoagulability caused by cancer. Regardless of the underlying cause, the obstruction of the portal vein can lead to the development of collateral veins within ten weeks, which can cause a range of complications.
Ascites is a common complication of portal vein thrombosis. In addition, if the thrombus extends into the mesenteric vein, it can lead to bowel ischemia, which is a serious condition that can cause abdominal pain, nausea, and vomiting. It is worth noting that portal vein obstruction usually does not affect liver function unless the organ is already diseased. However, the development of collateral veins can cause portal hypertension, which is a condition that increases pressure in the portal vein and can cause damage to the liver, spleen, and other organs.
There are inherited and acquired causes of portal vein obstruction. The inherited causes are protein C, protein S deficiency, prothrombin gene mutation, and factor V Leiden mutation.
Acquired causes are sepsis, malignancy, peripartum, burns, liver disease, oral contraceptives, and inflammatory diseases. In adults, most cases occur due to cirrhosis followed by neoplasms. In children, intra-abdominal infection causes most cases of portal vein obstruction.
The prognosis for this condition is generally good, with a 10-year mortality rate of 25% and an overall mortality rate of around 10%. However, if the patient has cirrhosis or cancer, the prognosis is worse and depends on the underlying condition.
Esophageal varices, which can be a complication of this condition, have a high mortality rate. Children usually have a better prognosis since the cause is rarely related to cancer or advanced liver disease.
Clinical History
Ascites is a common complication in patients with portal vein obstruction. In cases where malignancies are the primary cause of splenomegaly, signs of the neoplasm may also be evident. For example, patients with pancreatic carcinoma may present with fatigue and jaundice, while patients with hepatocellular carcinoma or cholangiocarcinoma may have jaundice and associated pruritis.
Splenomegaly is a common manifestation in patients with portal vein obstruction, and its incidence varies. In some cases, such as liver cirrhosis, additional signs like spider angiomata and palmar erythema may also be present due to increased pressure in the portal vein. Collaterals may also form, leading to the development of caput-medusae, hemorrhoids, and enlarged esophageal veins, which can result in upper gastrointestinal bleeding.
Physical Examination
Children with growth retardation may experience abnormalities in the extrahepatic biliary tree, which can occur due to compression from choledochal or periportal varices or ischemic stricturing. This can lead to a range of symptoms, including jaundice, hemobilia, cholangitis, cholecystitis, or a mass in the liver’s hilum region that can be mistaken for a cholangiocarcinoma.
Stigmata of chronic liver diseases, such as spider angiomata or palmar erythema, are often found with underlying liver disease. Mild hepatomegaly is also frequently present, as is tenderness in the right upper quadrant of the abdomen. It is important to note that these symptoms in a child may indicate an underlying liver disease or other medical condition.
Differential Diagnoses
Arsenic toxicity
Budd-Chiari syndrome
Cirrhosis
Primary biliary cirrhosis
Schistosomiasis
Sarcoidosis
Treatment of thrombosis in patients with cirrhosis can be challenging as balancing the use of anticoagulants with the risk of bleeding can be difficult. Selecting the appropriate anticoagulant can also be problematic, as each option has its benefits and drawbacks. LMWH and vitamin K antagonists have been successfully used to treat thrombosis in cirrhotic patients, but monitoring warfarin treatment can be challenging due to the patient’s baseline elevated INR.
Acute portal vein thrombosis should be treated with LMWH for at least three months and switched to oral anticoagulant agents after patient stabilization. Surgical modalities such as shunt surgery and the Sugiura procedure are options for treating portal vein occlusion associated with variceal bleeding. However, their use should be limited to recovery therapy when anticoagulation has failed, and invasive procedures are not contraindicated.
Shunt surgery is not recommended for patients with cirrhosis as it has a high mortality rate. Experts suggest endoscopic treatment and propranolol for patients with recurrent bleeding. If shunt surgery is necessary, a distal splenorenal shunt is recommended, with the option for splenectomy if the splenic vein is thrombosed.
https://www.ncbi.nlm.nih.gov/books/NBK541134/
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
